JPS6157810B2 - - Google Patents
Info
- Publication number
- JPS6157810B2 JPS6157810B2 JP53161137A JP16113778A JPS6157810B2 JP S6157810 B2 JPS6157810 B2 JP S6157810B2 JP 53161137 A JP53161137 A JP 53161137A JP 16113778 A JP16113778 A JP 16113778A JP S6157810 B2 JPS6157810 B2 JP S6157810B2
- Authority
- JP
- Japan
- Prior art keywords
- colostrum
- animals
- livestock
- lactic acid
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 28
- 210000003022 colostrum Anatomy 0.000 claims description 27
- 235000021277 colostrum Nutrition 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 23
- 241000894006 Bacteria Species 0.000 claims description 20
- 241000283690 Bos taurus Species 0.000 claims description 20
- 244000144972 livestock Species 0.000 claims description 16
- 239000004310 lactic acid Substances 0.000 claims description 14
- 235000014655 lactic acid Nutrition 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 11
- 239000005018 casein Substances 0.000 claims description 11
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 11
- 235000021240 caseins Nutrition 0.000 claims description 11
- 239000005862 Whey Substances 0.000 claims description 10
- 102000007544 Whey Proteins Human genes 0.000 claims description 10
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 238000009395 breeding Methods 0.000 claims description 5
- 230000001488 breeding effect Effects 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000282887 Suidae Species 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 7
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 7
- 229960004475 chlortetracycline Drugs 0.000 description 7
- 235000019365 chlortetracycline Nutrition 0.000 description 7
- 230000000384 rearing effect Effects 0.000 description 7
- 241000192125 Firmicutes Species 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- -1 ethanol Chemical compound 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 108010005090 rennin-like enzyme (Aspergillus ochraceus) Proteins 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は特に牛豚等の初生畜、すなわち離乳前
の幼畜に免疫性を与えるのに好適な添加剤の製造
方法に係るものである。
近年母畜の分娩後初生畜(以下離乳前の幼畜を
初生畜という)を直ちに母畜より隔離し、人工飼
育することが普及しつつあるが、これは、慢性伝
染病の予防、圧死、過剰出産による初生畜の事故
の防止、母畜の繁殖回転率の向上及び体力消耗の
回避等の見地から極めて望ましいことである。し
かし、人工飼育を行う場合、母乳の定時定量供給
は飼育者にとつてかなり負担となるばかりでな
く、母乳の清浄搾乳及び清浄保存は技術的にかな
り難しく、搾乳及び保存時に雑菌の混入及び増殖
が行われ、初生畜はこのような保存初乳の雑菌に
よつて下痢症状を呈するのがほとんどであり、一
旦下痢をおこすと、食欲が著しく減退し、死亡率
も高く、仮に成長しても飼料効率の悪い家畜とな
る。特に、未熟状態で出産した初生畜の場合は、
下痢を生じ易い体質であるため、保存状態の悪い
母乳による飼育は不可能である。また、市販の人
工乳を用いる場合には、衛生面での問題は解決さ
れるがコストが高くなり、離乳前の初生畜の母畜
からの蛋白に含まれる継承抗体であるγ―グロブ
リンが少量しか存在せず、離乳期後に自己形成す
る抗体が形成される迄の間は初生畜は疾病感染率
が極めて高い。
本発明者はこれら従来の幼畜の人工飼育の欠点
を改善すべく種々検討の結果、牛の初乳又は豚の
初乳を乳酸菌を用いて発酵させ、カゼインを分離
除去した免疫グロブリンを含有するホエイ(乳
清)を凍結乾燥することを特徴とした免疫グロブ
リンを含有する初生畜飼育用添加剤が優れた免疫
性附与効果を有し、幼畜の疾病感染及び下痢を防
止しそのことによる幼畜の死亡及び下痢を無くし
幼畜の飼育効率を高めることを見出し本発明を完
成したのである。
本発明の内容を詳しく説明すると、人の出生児
やうさぎの初生畜は免疫グロブリンを胎盤より受
け継いでいるが、牛、豚、羊等の初生畜は分娩時
に免疫グロブリンを受け継いでおらず、菌感染に
は無防備であり、哺乳により免疫グロブリンを腸
管細胞から吸収して血中に移動させる必要があ
る。
本発明では、人の飲料として出荷されずに無為
に廃業されている牛初乳を適当に処理することに
より、初生畜に免疫性を与える有用な適加剤とし
て利用出来ることを見出したものである。従来、
一般的な概念として腸管吸収細胞の機能には選択
性があつて、豚や馬等では同種動物間での免疫グ
ロブリンは容易に非選択的に吸収されるが他種動
物の免疫グロブリンの吸収には強い選択機能が働
くとされていた。ところが、本発明の処理法を用
いると、その理由は定かではないが、牛初乳より
得た粉末が免疫性附与剤として他種動物例えば豚
や馬等の初生畜に容易に作用して免疫性を附与す
ることを見出したものである。また豚の初乳につ
いては、自然哺乳の場合は母豚の乳等に付いてい
る雑菌が混入して下痢等を多発していたのを、本
発明の添加剤の形にすると、任意に人工乳等に添
加して豚及びそれ以外の初生畜に与えることが出
来、下痢症等に対し、著効を呈することが確認さ
れた。本発明による添加剤は、特に、豚の初生畜
に供与することが有効である。母豚は、品種改良
により、一回当りの出産頭数が多くなつており、
飼育効率は専ら出産された多数の初生畜を如何に
健全に飼育するかに係つており、一頭産の家畜に
比して、手間のかからない健全飼育飼料乃至その
添加物の出現がより望まれているからである。
本発明に於いて、牛の初乳又は豚の初乳を乳酸
菌を用いて醗酵させる理由は混入して来たグラム
陰性菌、グラム陽性菌、大腸菌、ブドウ球菌等の
雑菌の繁殖を抑制且減少させると共に消化及び栄
養吸収を促進させる為であり、第1図に牛初乳中
のグラム陽性菌数の繁殖の状態を、15℃で乳酸菌
醗酵させた場合曲線1に、蒸気滅菌して15℃で自
然醗酵させた場合を曲線2に、動物用オーレオマ
イシンを添加して保存させた場合を曲線3に示
す。第2図に牛初乳中のミクロコツカス・ブドウ
球菌数の繁殖の状態を15℃で乳酸菌醗酵させた場
合を曲線1に、蒸気滅菌して15℃で自然醗酵させ
た場合を曲線2に、動物用オーレオマイシンを添
加して保存させた場合を曲線3に示す。この第1
図及び第2図より乳酸菌を添加したものが菌を抑
制することの効果に優れることが解る。尚、乳酸
菌の添加量は牛初乳量に対して10%であり、動物
用オーレオマイシン(1g当りのクロルテトラサ
イクリン55mg力価含有)は牛初乳に対して
20ppm力価を添加したものである。豚初乳の場
合にも、以上の条件と異るところはない。
本発明の製造過程でカゼインを分離除去するの
は、免疫性グロブリンが主としてホエイ(乳清)
中に含まれ、カゼイン中にはほとんど含まれてい
ないためであり、濃度の高い免疫性γ―グロブリ
ンを得るためである。
上記に於ける、牛初乳又は豚の初乳を乳酸菌醗
酵させるには牛初乳又は豚初乳を醗酵槽中に移
し、温度5〜50℃、好ましくは15℃〜30℃前後で
48時間程度醗酵させれば良い。カゼインを分離し
てホエイを取り出すには、常法が適当出来る。例
えば酢酸、乳酸、ギ酸等の酸類を牛乳中に加えて
PHを4.6以下にする方法、エタノール等のアルコ
ールを添加する方法や凝乳酵素レンネツトを添加
する等の方法がある。
上記のようにしてカゼインを分離したホエイを
凍結乾燥するには通常の凍結乾燥機を使用してド
ライアイス、液体窒素、液体酸素等を使用して−
70℃〜0℃、好ましくは−30℃〜−10℃の温度で
行うのが良い。
このようにして得られるホエイの凍結乾燥粉末
は、全身感染症の防御に必要なγ―グロブリン
(IgG)や腸管感染症の防御作用をするγ―グロ
ブリン(IgA)等を多量に含有し、初生畜特に豚
の初生畜に与えると容易にこれを吸収して下痢症
をはじめとする諸種の疾病の発生が顕著に減少
し、畜混飼育効率を著しく高めることが出来る。
実施例 1
牛初乳100Kgを醗酵槽に移し、乳酸菌
(Lactobacillus)10Kgを添加撹拌混して15℃で48
時間醗酵させ、次いで酢酸を添加してPH4.5に調
整し5時間静置してカゼインを分離させ、ガラス
フイルター及び吸引ポンプを用いてカゼインを除
去しホエイ(乳清)を取り出した。この乳清を−
20℃で凍結乾燥して乳白色粉末を得た。
実施例 2
母豚34頭から生まれ仔豚374頭から任意に抽出
された150頭の初生豚を50頭ずつに各々3つに分
け、A群を母豚による自然飼育とし、B群の仔豚
には牛の初乳を与え、C群の仔豚には代用乳に実
施例1によつて得られた幼畜飼育用添加剤を5%
添加したものを与えた。その結果の死亡率(第1
表)下痢症発生頭(第2表及び体重の増加率(第
3図)を示す。
The present invention particularly relates to a method for producing an additive suitable for imparting immunity to primary livestock such as cows and pigs, that is, young livestock before weaning. In recent years, it has become popular to immediately isolate first-born animals from mother animals after parturition (hereinafter, young animals before weaning are referred to as first-born animals) from their mothers and raise them artificially. This is extremely desirable from the viewpoints of preventing accidents involving first-born livestock, improving the breeding turnover rate of mother livestock, and avoiding physical exhaustion. However, when artificial rearing is carried out, not only is it a considerable burden on the breeder to supply breast milk in a constant quantity, but also it is technically quite difficult to express and store the breast milk cleanly, and there is a risk of contamination and growth of bacteria during milking and storage. Most of the first-born animals exhibit diarrhea symptoms due to the bacteria in the stored colostrum. This results in livestock with poor feed efficiency. Especially in the case of first-time livestock that gave birth in an immature state,
Because they are prone to diarrhea, it is impossible to feed them with poorly preserved breast milk. In addition, when commercially available artificial milk is used, the problem of hygiene is solved, but the cost is high, and only a small amount of γ-globulin, an inherited antibody contained in the protein from the mother of first-bred animals before weaning, is used. However, until the self-generated antibodies are formed after weaning, the infection rate of first-born animals is extremely high. In order to improve the shortcomings of the conventional artificial rearing of young livestock, the present inventors have conducted various studies and found that cow colostrum or pig colostrum is fermented using lactic acid bacteria, and contains immunoglobulin from which casein has been separated and removed. An additive for breeding primary livestock containing immunoglobulin, which is produced by freeze-drying whey, has an excellent immunity-improving effect, and prevents disease infection and diarrhea in young animals. They discovered that the death and diarrhea of young animals can be eliminated and the efficiency of rearing young animals can be improved, and the present invention has been completed. To explain the content of the present invention in detail, first-born animals such as human babies and rabbits inherit immunoglobulin from the placenta, but first-born animals such as cows, pigs, and sheep do not inherit immunoglobulin at the time of parturition, and bacteria They are defenseless against infection, and immunoglobulins must be absorbed from intestinal cells and transferred into the blood through suckling. In the present invention, it has been discovered that by appropriately processing bovine colostrum, which is not shipped as a human beverage and has been put out of business, it can be used as a useful additive that imparts immunity to first-generation livestock. be. Conventionally,
As a general concept, there is selectivity in the function of intestinal absorption cells; in pigs, horses, etc., immunoglobulins between animals of the same species are easily absorbed in a non-selective manner, but immunoglobulins from animals of other species are absorbed easily. was thought to have a strong selection function. However, when the treatment method of the present invention is used, the powder obtained from bovine colostrum can easily act as an immunity-enhancing agent on primary livestock such as pigs and horses, although the reason for this is not clear. It was discovered that it confers immunity. In addition, with regard to colostrum of pigs, in the case of natural suckling, contamination with bacteria from the sow's milk caused frequent diarrhea, etc., but when it is in the form of the additive of the present invention, it can be artificially produced. It has been confirmed that it can be added to milk and given to pigs and other primary livestock, and is highly effective against diarrheal diseases. The additive according to the present invention is particularly effective when applied to first-generation pigs. Due to breeding improvements, sows are able to give birth to more pigs at a time.
The efficiency of rearing depends solely on how to raise a large number of newly born livestock in a healthy manner, and compared to single-head livestock, it is more desirable to develop healthy rearing feeds and their additives that require less effort. Because there is. In the present invention, the reason why cow colostrum or pig colostrum is fermented using lactic acid bacteria is to suppress and reduce the propagation of contaminating bacteria such as Gram-negative bacteria, Gram-positive bacteria, Escherichia coli, and Staphylococcus. Figure 1 shows the state of reproduction of the number of Gram-positive bacteria in bovine colostrum. Curve 1 shows the number of gram-positive bacteria in bovine colostrum when fermented with lactic acid bacteria at 15℃. Curve 2 shows the case where fermentation was carried out naturally, and curve 3 shows the case where the animal was preserved with the addition of aureomycin for animals. Figure 2 shows the state of reproduction of Micrococcus and Staphylococcus in bovine colostrum. Curve 1 shows the case of lactic acid bacteria fermentation at 15℃, Curve 2 shows the case of steam sterilization and natural fermentation at 15℃, Curve 3 shows the case where aureomycin was added and stored. This first
From the figure and FIG. 2, it can be seen that the product containing lactic acid bacteria has an excellent effect of inhibiting bacteria. The amount of lactic acid bacteria added is 10% of the amount of bovine colostrum, and the amount of aureomycin for animals (containing a titer of 55 mg of chlortetracycline per gram) is 10% of the amount of bovine colostrum.
20ppm titer added. In the case of pig colostrum, the above conditions are no different. In the production process of the present invention, casein is separated and removed because immune globulin is mainly extracted from whey (whey).
This is because it is contained in casein, but hardly contained in casein, and the purpose is to obtain a high concentration of immune γ-globulin. In order to ferment bovine colostrum or porcine colostrum with lactic acid bacteria in the above, transfer the bovine colostrum or porcine colostrum into a fermenter at a temperature of 5 to 50°C, preferably around 15 to 30°C.
It should be fermented for about 48 hours. Conventional methods can be used to separate casein and extract whey. For example, by adding acids such as acetic acid, lactic acid, and formic acid to milk.
There are methods such as reducing the pH to 4.6 or less, adding alcohol such as ethanol, and adding milk-clotting enzyme rennet. To freeze-dry the whey from which casein has been separated as described above, use a normal freeze dryer and use dry ice, liquid nitrogen, liquid oxygen, etc.
The temperature is preferably 70°C to 0°C, preferably -30°C to -10°C. The whey freeze-dried powder obtained in this way contains large amounts of γ-globulin (IgG), which is necessary for the defense against systemic infections, and γ-globulin (IgA), which has a protective effect against intestinal infections. When given to livestock, especially newborn pigs, it is easily absorbed, significantly reducing the incidence of various diseases including diarrhea, and significantly increasing the efficiency of mixed rearing of livestock. Example 1 100 kg of bovine colostrum was transferred to a fermentation tank, 10 kg of lactic acid bacteria (Lactobacillus) was added, stirred, and incubated at 15°C for 48 hours.
Fermentation was carried out for a period of time, and then acetic acid was added to adjust the pH to 4.5, and the mixture was allowed to stand for 5 hours to separate casein. Casein was removed using a glass filter and a suction pump, and whey was taken out. This whey-
Freeze-drying was performed at 20°C to obtain a milky white powder. Example 2 150 day-old piglets randomly selected from 374 piglets born to 34 sows were divided into three groups of 50 each, group A was naturally reared by the mother pigs, and group B piglets were reared naturally by the mother pigs. Feed cow colostrum, and piglets in group C receive 5% of the additive for raising young stock obtained in Example 1 in the milk replacer.
I was given something added. The resulting mortality rate (first
Table) Diarrhea cases (Table 2) and body weight increase rate (Figure 3) are shown.
【表】【table】
【表】
実施例 3
豚初乳90Kgを醗酵槽に移し、乳酸菌
(Lactobacillus)8Kgを添加撹拌混合して15℃で
48時間醗酵させ、次いで酢酸を用いてPH4.5に調
整し5時間静置してカゼインを分離させ、布を用
いてカゼインを除去しホエイ(乳清)を取り出し
た。このホエイを−20℃で凍結乾燥して乳白色粉
末を得た。
実施例 4
母豚32頭から生れた仔豚325頭から任意に抽出
された150頭の初生豚を50頭ずつに各々3つに分
け、A群を母豚による自然飼育とし、B群の仔豚
には牛の初乳を与え、C群の仔豚には代用乳に実
施例3によつて得られた幼畜飼育用添加剤を0.8
%添加したものを与えた。その結果の死亡率(第
3表)下痢症発生頭(第4表)を示す。[Table] Example 3 90 kg of pig colostrum was transferred to a fermentation tank, 8 kg of lactic acid bacteria (Lactobacillus) was added, stirred and mixed, and the mixture was heated at 15°C.
The mixture was fermented for 48 hours, then adjusted to pH 4.5 using acetic acid, left to stand for 5 hours to separate casein, and the casein was removed using a cloth to extract whey. This whey was freeze-dried at -20°C to obtain a milky white powder. Example 4 150 day-old piglets arbitrarily selected from 325 piglets born from 32 mother pigs were divided into three groups of 50 piglets each. Group A was naturally reared by the mother pigs, and group B piglets were reared naturally. were given cow colostrum, and piglets in group C were given 0.8 g of the additive for raising young stock obtained in Example 3 in the milk replacer.
% added. The resulting mortality rates (Table 3) and cases of diarrhea (Table 4) are shown.
【表】【table】
第1図は、牛初乳中の大腸菌数を示すグラフで
あり、1は乳酸菌を添加して15℃で醗酵させたも
の、2は蒸気滅菌して15℃で自然醗酵させたも
の、3は動物用オーレオマイシンを添加して保存
したものである。
第1図は、牛初乳中のグラム陽性菌数を示すグ
ラフであり、1は乳酸菌を添加して15℃で醗酵さ
せたもの、2は蒸気滅菌して15℃で自然醗酵させ
たもの、3は動物用オーレオマイシンを添加して
保存したものである。
第2図は、牛初乳中のミクロコツカス・ブドウ
球菌数を示すグラフであり、1は乳酸菌を添加し
て15℃で醗酵させたもの、2は蒸気滅菌して15℃
で自然醗酵させたもの、3は動物用オーレオマイ
シンを添加して保存したものである。
第3図は初生畜の発育曲線を示したものであ
り、1は人工乳に本発明の幼畜飼育用添加剤を添
加したもの、2は母豚自然哺乳によるものであ
る。
Figure 1 is a graph showing the number of Escherichia coli in bovine colostrum; 1 is for milk that was fermented at 15°C with addition of lactic acid bacteria, 2 is for steam sterilized and naturally fermented at 15°C, and 3 is for milk that was naturally fermented at 15°C. It is preserved with the addition of animal grade aureomycin. Figure 1 is a graph showing the number of Gram-positive bacteria in bovine colostrum; 1 is for fermentation at 15°C with addition of lactic acid bacteria; 2 is for steam sterilization and natural fermentation at 15°C; No. 3 was preserved with the addition of animal grade aureomycin. Figure 2 is a graph showing the number of Micrococcus and Staphylococcus in bovine colostrum; 1 is the one obtained by adding lactic acid bacteria and fermented at 15℃, and 2 is the one obtained by steam sterilization at 15℃.
No. 3 was naturally fermented, and No. 3 was preserved with the addition of animal grade aureomycin. FIG. 3 shows the growth curves of first-bred animals; 1 is the one obtained by adding the additive for rearing young animals of the present invention to artificial milk, and 2 is the one obtained by natural suckling of the mother pig.
Claims (1)
させ、カゼインを分離除去した免疫グロブリンを
含有するホエイ(乳清)を凍結乾燥することを特
徴とする初生畜飼育用添加剤の製造方法。 2 上記の凍結乾燥の温度は−30℃〜−10℃であ
ることを特徴とする特許請求の範囲第1項記載の
初生畜飼育用添加剤の製造方法。[Scope of Claims] 1. A first-generation animal characterized by fermenting bovine colostrum or pig colostrum using lactic acid bacteria and freeze-drying whey containing immunoglobulins from which casein has been separated and removed. A method for producing breeding additives. 2. The method for producing an additive for breeding primary livestock according to claim 1, wherein the freeze-drying temperature is -30°C to -10°C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16113778A JPS5589233A (en) | 1978-12-28 | 1978-12-28 | Preparation of additive for breeding of new born cattle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16113778A JPS5589233A (en) | 1978-12-28 | 1978-12-28 | Preparation of additive for breeding of new born cattle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5589233A JPS5589233A (en) | 1980-07-05 |
| JPS6157810B2 true JPS6157810B2 (en) | 1986-12-09 |
Family
ID=15729288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16113778A Granted JPS5589233A (en) | 1978-12-28 | 1978-12-28 | Preparation of additive for breeding of new born cattle |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5589233A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020021908A (en) * | 2000-09-18 | 2002-03-23 | 허강칠 | Healthful auxiliary food Made from Whey |
| EP2138187A1 (en) | 2008-06-24 | 2009-12-30 | Nestec S.A. | Probiotics, secretory IgA and infection |
| EP2138186A1 (en) * | 2008-06-24 | 2009-12-30 | Nestec S.A. | Probiotics, secretory IgA and inflammation |
-
1978
- 1978-12-28 JP JP16113778A patent/JPS5589233A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5589233A (en) | 1980-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4377569A (en) | Method of treating animals to resist infectious diseases | |
| McClellan et al. | Evolution of lactation: nutrition v. protection with special reference to five mammalian species | |
| Jensen et al. | Development of intestinal immunoglobulin absorption and enzyme activities in neonatal pigs is diet dependent | |
| US4816252A (en) | Product and process for transferring passive immunity to newborn domestic animals using ultrafiltered whey containing immunoglobulins | |
| Louca et al. | The effect of early weaning on the lactation performance of Damascus goats and the growth rate of the kids | |
| JPH01502110A (en) | Immunologically active whey fractionation and recovery method | |
| Kesler | Feeding mastitic milk to calves | |
| US5645834A (en) | Method and product for treating failure of passive transfer and improving milk production in bovine species | |
| US4141970A (en) | Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections | |
| EP0074240A2 (en) | Antibodies specific to endotoxins | |
| Muller et al. | Performance of calves fed fermented colostrum or colostrum with additives during warm ambient temperatures | |
| Wise et al. | Responses of calves to open-pail and nipple-pail systems of milk feeding | |
| JPS6157810B2 (en) | ||
| Porter | Structural and functional characteristics of immunoglobulins of the common domestic species | |
| JPS5947581B2 (en) | How to raise young livestock | |
| McKusick et al. | Effects of three weaning and rearing systems on commercial milk production and lamb growth | |
| RU2671634C2 (en) | Stimulant for increasing colostral immunity and nonspecific resistance - “synestrol 2 %” and a method for increasing clostral immunity and nonspecific resistance | |
| Keys et al. | Performance of calves fed fermented mastitic milk, colostrum, and fresh whole milk | |
| CN114027406B (en) | Feed simultaneously applicable to perinatal sow and lactation piglet and preparation method | |
| Bahroz et al. | Immunity Development in Newborn Calves: a Review. | |
| IE43372B1 (en) | Methods for improving the resistance of non-human mammals to gastro-intestinal disorders | |
| CN113845588B (en) | Preparation method and application of yolk antibody for resisting porcine rotavirus | |
| Hill | The abomasum. | |
| US6296879B1 (en) | Ruminal fluid inoculation of calves | |
| RU2812359C1 (en) | Method of increasing safety of new-born calves |